| 前收市價 | 64.95 |
| 開市 | 64.95 |
| 買盤 | 65.27 x 100 |
| 賣出價 | 65.66 x 100 |
| 今日波幅 | 64.68 - 65.60 |
| 52 週波幅 | 37.06 - 70.81 |
| 成交量 | |
| 平均成交量 | 145,382 |
| 市值 | 1.372B |
| Beta 值 (5 年，每月) | 0.80 |
| 市盈率 (最近 12 個月) | 76.93 |
| 每股盈利 (最近 12 個月) | 0.85 |
| 業績公佈日 | 2024年5月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 79.80 |
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
- Zacks
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
ZacksGSK Announces FDA Acceptance of New Meningococcal Jab BLA
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
